Next generation sequencing in bleeding disorders: two novel variants in the F5 gene (Valencia-1 and Valencia-2) associated with mild factor V deficiency.


Journal

Journal of thrombosis and thrombolysis
ISSN: 1573-742X
Titre abrégé: J Thromb Thrombolysis
Pays: Netherlands
ID NLM: 9502018

Informations de publication

Date de publication:
Nov 2019
Historique:
pubmed: 4 7 2019
medline: 11 3 2020
entrez: 4 7 2019
Statut: ppublish

Résumé

Inherited bleeding coagulation disorders (IBCDs) have a powerful diagnostic tool in next generation sequencing (NGS) that not only offers confirmation of diagnosis but also aids in genetic counselling, prenatal diagnosis and helps to predict the clinical course and follow-up of a disease. In our group, targeted-NGS using a Custom SureSelect QXT Panel (Agilent Technologies, Inc., Santa Clara, CA, USA) was designed to screen for causal variants in 40 genes related with the coagulation cascade. In this work, we used NGS for screening all the coding and intronic boundary regions of F5 gene in two patients affected by factor V (FV) deficiency (parahemophilia). Two new mutations were found: c.4745A>G (p.Tyr1582Cys, NM_000130.4) and c.1999_2002dupAATT (p.Ser668ter; NM_000130.4), both located in exon 13 of the F5 gene. We designated them Valencia-1 and Valencia-2 respectively. Valencia-1 could provoke loss of the fifth cupredoxin domain of the FV, and would be responsible for its defective activity. Valencia-2 prematurely stops the translation of mRNA, resulting in a truncated FV protein which lacks completely the B domain and the light chain. NGS has permitted to describe an increasing number of FV deficiency-causing mutations and a better understanding of FV's structure and function. The description of deficiency-causing mutations will continue to increase our knowledge of the functional residues of FV, as well as those which are involved in the correct folding of the protein. In this sense, NGS is a useful tool for studying IBCDs, as permits studying the whole coagulation cascade at once and gives a global view of the patient's genetic background.

Identifiants

pubmed: 31267299
doi: 10.1007/s11239-019-01911-z
pii: 10.1007/s11239-019-01911-z
doi:

Substances chimiques

Codon, Nonsense 0
Factor V 9001-24-5

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

674-678

Références

Blood. 2001 Mar 15;97(6):1549-54
pubmed: 11238089
Semin Thromb Hemost. 2009 Jun;35(4):382-9
pubmed: 19598066
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Blood. 2015 Mar 12;125(11):1822-5
pubmed: 25634741
J Thromb Haemost. 2007 Jan;5(1):185-8
pubmed: 17059427
Haemophilia. 2009 Sep;15(5):1143-53
pubmed: 19486170

Auteurs

A Moret (A)

Unidad de Hemostasia y Trombosis, Hospital Universitario y Politécnico La Fe, Valencia, Spain.

Ángel Zúñiga (Á)

Unidad de Genética, Hospital Universitario y Politécnico La Fe, Valencia, Spain. zunyiga_ang@gva.es.

M Ibáñez (M)

Servicio de Hematología, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto Carlos III, Madrid, Spain.
Departamento de Ciencias Biomédicas, Facultad de Ciencias de la Salud, Universidad CEU Cardenal Herrera, Valencia, Spain.

A R Cid (AR)

Unidad de Hemostasia y Trombosis, Hospital Universitario y Politécnico La Fe, Valencia, Spain.

S Haya (S)

Unidad de Hemostasia y Trombosis, Hospital Universitario y Politécnico La Fe, Valencia, Spain.

F Ferrando (F)

Unidad de Hemostasia y Trombosis, Hospital Universitario y Politécnico La Fe, Valencia, Spain.

A Blanquer (A)

Unidad de Hemostasia y Trombosis, Hospital Universitario y Politécnico La Fe, Valencia, Spain.

J Cervera (J)

Unidad de Genética, Hospital Universitario y Politécnico La Fe, Valencia, Spain.

S Bonanad (S)

Unidad de Hemostasia y Trombosis, Hospital Universitario y Politécnico La Fe, Valencia, Spain.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH